Medical device dealmaking has been fairly quiet for most of 2025. Aside from a few bursts of activity, medtech companies have not spent money as they typically have, partly due to macroeconomic factors like higher interest rates and unpredictable tariff policies from the Trump administration. While M&A may be slower this year, executives from Stryker and Johnson & Johnson see M&A as a crucial part of their business strategies — and they are ready to make deals. “M&A is a huge part of our strategy. It is part of our offense,” Stryker CEO Kevin Lobo said during a panel at AdvaMed’s The MedTech Conference.
Read the full article: Medtech M&A Has Remained Slow This Year. But 2 Execs Are Ready to Make a Deal //
Source: https://www.medtechdive.com/news/stryker-jnj-dealmaking-advamed-conference/802299/